Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $82.00 at Royal Bank Of Canada

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective lifted by Royal Bank Of Canada from $80.00 to $82.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

XENE has been the topic of a number of other research reports. Wedbush lowered their target price on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, March 16th. Jefferies Financial Group set a $100.00 price target on Xenon Pharmaceuticals in a research note on Monday, March 9th. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target for the company. JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Finally, HC Wainwright raised their price objective on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $74.50.

Xenon Pharmaceuticals Stock Up 0.8%

Shares of NASDAQ XENE opened at $56.44 on Friday. The firm’s 50-day moving average price is $54.64 and its 200-day moving average price is $46.62. Xenon Pharmaceuticals has a 52-week low of $28.19 and a 52-week high of $63.95. The company has a market cap of $5.45 billion, a PE ratio of -12.01 and a beta of 0.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting the consensus estimate of ($1.17). During the same quarter in the previous year, the firm earned ($0.83) EPS. As a group, equities research analysts anticipate that Xenon Pharmaceuticals will post -4.83 EPS for the current fiscal year.

Insider Activity at Xenon Pharmaceuticals

In other news, insider Andrea Difabio sold 1,342 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $74,118.66. Following the sale, the insider directly owned 7,301 shares in the company, valued at approximately $403,234.23. This represents a 15.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ian Mortimer sold 7,308 shares of the firm’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 296,707 shares of company stock valued at $17,845,365 over the last 90 days. 4.07% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of XENE. PNC Financial Services Group Inc. increased its holdings in shares of Xenon Pharmaceuticals by 23.2% during the first quarter. PNC Financial Services Group Inc. now owns 8,097 shares of the biopharmaceutical company’s stock valued at $471,000 after acquiring an additional 1,523 shares in the last quarter. KBC Group NV lifted its position in Xenon Pharmaceuticals by 4,540.6% during the 1st quarter. KBC Group NV now owns 129,010 shares of the biopharmaceutical company’s stock worth $7,502,000 after acquiring an additional 126,230 shares during the period. Swiss National Bank boosted its position in Xenon Pharmaceuticals by 38.3% in the first quarter. Swiss National Bank now owns 157,700 shares of the biopharmaceutical company’s stock valued at $9,170,000 after buying an additional 43,700 shares during the last quarter. Jennison Associates LLC boosted its position in Xenon Pharmaceuticals by 2.1% in the first quarter. Jennison Associates LLC now owns 1,318,814 shares of the biopharmaceutical company’s stock valued at $76,689,000 after buying an additional 26,759 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in Xenon Pharmaceuticals in the 1st quarter worth approximately $13,963,000. 95.45% of the stock is currently owned by institutional investors.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Royal Bank of Canada raised its price target on Xenon Pharmaceuticals from $80 to $82 and reaffirmed an outperform rating, signaling confidence in further upside. RBC price target update
• Positive Sentiment: Xenon reported Q1 2026 earnings of -$1.17 per share, matching analyst expectations and reducing uncertainty around the quarter. The company also said it provided a business update alongside the results. Q1 2026 financial results and business update
• Neutral Sentiment: Needham & Company lowered its price target slightly from $80 to $78 but kept a buy rating, which still points to substantial upside from current levels. Needham price target update
• Neutral Sentiment: The company’s earnings call transcript and earnings snapshot are drawing investor attention, but no additional major surprise was highlighted in the available items. Q1 2026 earnings call transcript

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.